文献速递神经肿瘤

脑肿瘤囊肿液DNA中遗传变异的可靠检测用于诊断

Reliable detection of genetic alterations in cyst fluid DNA for the diagnosis of brain tumors.
PubMed 文献 · J Neurooncol · 2024-01-16

本研究对22例囊性脑肿瘤患者的囊肿液cfDNA进行检测,评估其是否可替代肿瘤DNA用于诊断。ddPCR在囊肿液cfDNA中检出全部25个(100%)遗传变异,Sanger测序检出20个(80%)。MLPA在17例弥漫性胶质瘤中的11例(65%)可行,且与肿瘤DNA结果高度相关。结论认为囊肿液cfDNA是诊断脑肿瘤时肿瘤DNA的可靠替代。

要点

  • ddPCR在囊肿液cfDNA中检出全部25个(100%)肿瘤DNA遗传变异。
  • Sanger测序在囊肿液cfDNA中检出20/25个(80%)遗传变异。
  • MLPA在11/17例(65%)弥漫性胶质瘤中可行,结果与肿瘤DNA高度相关。

核心结论

  • 囊性脑肿瘤囊肿液中的游离DNA是诊断脑肿瘤时肿瘤DNA的可靠替代。

研究设计与样本

  • 研究纳入22例接受手术的囊性脑肿瘤患者,其肿瘤DNA中均已确认存在遗传变异。
  • 基于WHO 2021分类进行病理诊断,肿瘤DNA的诊断性变异如少突胶质细胞瘤的IDH1 R132H和TERT启动子突变通过Sanger测序检测。
  • 囊肿液cfDNA中相同变异通过微滴数字PCR(ddPCR)和Sanger测序分析,并用多重连接依赖探针扩增(MLPA)评估1p/19q状态、CDKN2A缺失、PTEN缺失和EGFR扩增。

主要发现

  • 22份肿瘤样本中共发现25个遗传变异。
  • ddPCR在囊肿液cfDNA中检出全部25个(100%)变异。
  • Sanger测序在囊肿液cfDNA中检出25个中的20个(80%)变异。
  • 囊肿液cfDNA的变异等位基因频率与肿瘤DNA相当(R=0.62,Pearson相关)。
  • MLPA在17例弥漫性胶质瘤中的11例(65%)可行,肿瘤DNA与囊肿液cfDNA结果高度相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Liquid biopsy of cyst fluid in brain tumors has not been extensively studied to date. The present study was performed to see whether diagnostic genetic alterations found in brain tumor tissue DNA could also be detected in cell-free DNA (cfDNA) of cyst fluid in cystic brain tumors. METHODS: Cyst fluid was obtained from 22 patients undergoing surgery for a cystic brain tumor with confirmed genetic alterations in tumor DNA. Pathological diagnoses based on WHO 2021 classification and diagnostic alterations in the tumor DNA, such as IDH1 R132H and TERT promoter mutation for oligodendrogliomas, were detected by Sanger sequencing. The same alterations were analyzed by both droplet digital PCR (ddPCR) and Sanger sequencing in cyst fluid cfDNA. Additionally, multiplex ligation-dependent probe amplification (MLPA) assays were performed to assess 1p/19q status, presence of CDKN2A loss, PTEN loss and EGFR amplification, to assess whether differentiating between astrocytomas and oligodendrogliomas and grading is possible from cyst fluid cfDNA. RESULTS: Twenty-five genetic alterations were found in 22 tumor samples. All (100%) alterations were detected in cyst fluid cfDNA by ddPCR. Twenty of the 25 (80%) alterations were also detected by Sanger sequencing of cyst fluid cfDNA. Variant allele frequency (VAF) in cyst fluid cfDNA was comparable to that of tumor DNA (R = 0.62, Pearson's correlation). MLPA was feasible in 11 out of 17 (65%) diffuse gliomas, with close correlation of results between tumor DNA and cyst fluid cfDNA. CONCLUSION: Cell-free DNA obtained from cyst fluid in cystic brain tumors is a reliable alternative to tumor DNA when diagnosing brain tumors.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. On J, Natsumeda M, Takahashi H, et al. Reliable detection of genetic alterations in cyst fluid DNA for the diagnosis of brain tumors. J Neurooncol. 2024. PMID: 38227143. doi:10.1007/s11060-023-04555-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。